According to Spherix Global Insights and EU5 nephrologists are anticipating a more dynamic and competitive HIF-PH inhibitor market Exton, PA,
Spherix Global Insights finds gastroenterologist and hepatologist capacity is being stretched to the limit by increasing demand from MASLD/MASH patients
After early adoption, overall use of Olumiant in alopecia areata is beginning to level-off, according to Spherix Global Insights Exton,
Lack of vision improvement, amongst other efficacy concerns, as well as potential for conversion to neovascular age-related macular degeneration are
Uptake and user-base of Byooviz (Biogen) and Cimerli (Coherus) have both been low while general attitudes around biosimilars seem to
In the third annual patient chart analysis, major treatment shifts in biologic use and average daily steroid dose were observed.
Adalimumab biosimilars hold potential to grow the overall biologic-treated population, but only if the cost savings translate to patients and
Despite Vabysmo’s positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron’s
Ferring Pharmaceutical’s achieved an innovative milestone in C.Diff treatment when it launched Rebyota, the first FDA approved Fecal Microbiota Transplant
New Spherix research highlights existing need for innovation in this underserved population EXTON, Pa., May 22, 2023 — The non-alcoholic
Online platform underscores Spherix’s commitment to innovation by providing dynamic solutions generated from the company’s comprehensive insights library of reports
Recent research suggests AbbVie has managed gastroenterologists’ concerns regarding JAK safety, setting up a potentially favorable encore in the Crohn’s
